# Mark Yarchoan

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/mark-yarchoan/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,441 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 52 |
| i10-index | 109 |
| Last Known Institution | Bloomberg (United States) |
| OpenAlex ID | https://openalex.org/A5076456783 |
| ORCID iD | https://orcid.org/0000-0003-4401-0748 |
| Works | 499 |

## Researcher papers

- [Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic](https://scholariq.org/papers/development-of-tumor-mutation-burden-as-an-immunotherapy-biomarker-utility-for/)
- [Neoadjuvant cabozantinib and nivolumab convert locally advanced hepatocellular carcinoma into resectable disease with enhanced antitumor immunity](https://scholariq.org/papers/neoadjuvant-cabozantinib-and-nivolumab-convert-locally-advanced-hepatocellular/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Pancreatic and Hepatic Oncology Research](https://scholariq.org/topics/pancreatic-and-hepatic-oncology-research/)
- [Hepatocellular Carcinoma Treatment and Prognosis](https://scholariq.org/topics/hepatocellular-carcinoma-treatment-and-prognosis/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Cholangiocarcinoma and Gallbladder Cancer Studies](https://scholariq.org/topics/cholangiocarcinoma-and-gallbladder-cancer-studies/)

## Researcher university

- [Bloomberg (United States)](https://scholariq.org/institutions/bloomberg-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.